| NASH limits anti-tumour surveillance in immunotherapy-treated HCC D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter, M Szydlowska, ... Nature 592 (7854), 450-456, 2021 | 787 | 2021 |
| Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis FE Mózes, JA Lee, EA Selvaraj, ANA Jayaswal, M Trauner, J Boursier, ... Gut 71 (5), 1006-1019, 2022 | 285 | 2022 |
| Lean NAFLD: a distinct entity shaped by differential metabolic adaptation F Chen, S Esmaili, GB Rogers, E Bugianesi, S Petta, G Marchesini, ... Hepatology 71 (4), 1213-1227, 2020 | 279 | 2020 |
| NASH in lean individuals R Younes, E Bugianesi Seminars in liver disease 39 (01), 086-095, 2019 | 232 | 2019 |
| Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis O Govaere, S Cockell, D Tiniakos, R Queen, R Younes, M Vacca, ... Science translational medicine 12 (572), eaba4448, 2020 | 226 | 2020 |
| Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis EA Selvaraj, FE Mózes, ANA Jayaswal, MH Zafarmand, Y Vali, JA Lee, ... Journal of hepatology 75 (4), 770-785, 2021 | 199 | 2021 |
| Epidemiology and natural history of patients with NAFLD N Bhala, R Ibrahim Kamal Jouness, E Bugianesi Current pharmaceutical design 19 (29), 5169-5176, 2013 | 196 | 2013 |
| Should we undertake surveillance for HCC in patients with NAFLD? R Younes, E Bugianesi Journal of hepatology 68 (2), 326-334, 2018 | 180 | 2018 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 166 | 2022 |
| Progression and natural history of nonalcoholic fatty liver disease in adults A Marengo, RIK Jouness, E Bugianesi Clinics in liver disease 20 (2), 313-324, 2016 | 166 | 2016 |
| Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease C Rosso, K Kazankov, R Younes, S Esmaili, M Marietti, M Sacco, F Carli, ... Journal of hepatology 71 (5), 1012-1021, 2019 | 159 | 2019 |
| Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? R Younes, O Govaere, S Petta, L Miele, D Tiniakos, A Burt, E David, ... Gut 71 (2), 382-390, 2022 | 141 | 2022 |
| Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease R Younes, GP Caviglia, O Govaere, C Rosso, A Armandi, T Sanavia, ... Journal of hepatology 75 (4), 786-794, 2021 | 123 | 2021 |
| The macrophage activation marker sCD 163 is associated with morphological disease stages in patients with non‐alcoholic fatty liver disease K Kazankov, F Barrera, HJ Møller, C Rosso, E Bugianesi, E David, ... Liver International 36 (10), 1549-1557, 2016 | 116 | 2016 |
| Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver … S Petta, G Sebastiani, M Viganò, J Ampuero, VWS Wong, J Boursier, ... Clinical gastroenterology and hepatology 19 (4), 806-815. e5, 2021 | 103 | 2021 |
| Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease M Boyle, D Tiniakos, JM Schattenberg, V Ratziu, E Bugianessi, S Petta, ... Jhep Reports 1 (3), 188-198, 2019 | 102 | 2019 |
| The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease T Hardy, K Wonders, R Younes, GP Aithal, R Aller, M Allison, P Bedossa, ... Contemporary clinical trials 98, 106175, 2020 | 97 | 2020 |
| Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease C Rosso, L Mezzabotta, M Gaggini, F Salomone, R Gambino, A Marengo, ... Hepatology 63 (1), 107-116, 2016 | 83 | 2016 |
| Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease O Govaere, SK Petersen, N Martinez-Lopez, J Wouters, M Van Haele, ... Journal of hepatology 76 (5), 1001-1012, 2022 | 72 | 2022 |
| Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta … FE Mózes, JA Lee, Y Vali, O Alzoubi, K Staufer, M Trauner, R Paternostro, ... The Lancet Gastroenterology & Hepatology 8 (8), 704-713, 2023 | 47 | 2023 |
